Erlotinib manufacturer and R&D background

Erlotinib (Erlotinib) is a small molecule targeted drug developed and produced by the pharmaceutical company Roche. It is an EGFR tyrosine kinase inhibitor. Its research and development background stems from in-depth research on the epidermal growth factor receptor (EGFR) signaling pathway at the end of the last century. At that time, scientists discovered that EGFR gene mutations are closely related to the occurrence and development of non-small cell lung cancer (NSCLC), and by specifically blocking its downstream signals, they can effectively inhibit tumor cell proliferation and induce apoptosis. Under this research idea, erlotinib was successfully developed and was approved by the U.S. FDA in 2004 for second-line or third-line treatment of non-small cell lung cancer, and then gradually expanded to first-line treatment and pancreatic cancer and other indications.

As one of the important targeted drugs launched by Roche, the successful launch of erlotinib marksEGFR inhibitors have entered the clinical mainstream. It can exert a significant effect on patients with EGFR exon 19 deletion or exon 21 L858R mutation, which is the key to distinguishing it from traditional chemotherapy. Unlike chemotherapy drugs, which do not selectively kill rapidly dividing cells, erlotinib precisely inhibits the molecular signals of tumor cells, making the treatment more targeted and improving the patient's quality of life to a considerable extent.

During the research and development process, erlotinib and the then first-generationEGFR inhibitors jointly promoted the development of precision medicine and created a new era of targeted therapy. With the promotion of its application, erlotinib has been gradually approved for use worldwide and has accumulated a lot of experience in clinical practice. Today, although a new generation of EGFR-targeted drugs has appeared on the market, erlotinib still retains an important position in some patients, especially in the field of pancreatic cancer treatment, where it is still one of the few approved targeted drugs.

Reference materials:https://en.wikipedia.org/wiki/Erlotinib